Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:CYBNNASDAQ:RNAZNASDAQ:SLSNASDAQ:VTL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYBNCybin$8.34+11.6%$6.70$4.81▼$13.88$160.43M0.6253,841 shs558,772 shsRNAZTransCode Therapeutics$6.87-1.4%$11.40$6.15▼$1,838.76$5.72M1.52100,145 shs41,015 shsSLSSELLAS Life Sciences Group$1.93+2.1%$1.39$0.77▼$2.12$192.57M2.341.50 million shs4.28 million shsVTLVital Therapies$0.89-3.0%$8.88$0.15▼$9.75$37.71M3.5121.62 million shs822,036 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYBNCybin+11.65%+18.97%+19.31%+0.97%+2,160.16%RNAZTransCode Therapeutics-1.43%-2.00%-35.43%-92.68%-99.99%SLSSELLAS Life Sciences Group+2.12%-0.52%+37.86%+67.83%+37.86%VTLVital Therapies0.00%-4.49%-17.33%-20.21%-26.59%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCYBNCybin2.5711 of 5 stars3.60.00.00.03.20.81.3RNAZTransCode Therapeutics2.5317 of 5 stars3.52.00.00.04.20.01.3SLSSELLAS Life Sciences Group0.4046 of 5 stars0.02.00.00.03.50.00.6VTLVital TherapiesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYBNCybin 3.25Buy$86.00931.18% UpsideRNAZTransCode Therapeutics 3.00Buy$280.003,975.69% UpsideSLSSELLAS Life Sciences Group 0.00N/AN/AN/AVTLVital Therapies 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest VTL, SLS, CYBN, and RNAZ Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/13/2025CYBNCybinCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/16/2025RNAZTransCode TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$560.00 ➝ $280.003/13/2025CYBNCybinGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$35.003/13/2025RNAZTransCode TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$560.00 ➝ $560.00(Data available from 5/28/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYBNCybinN/AN/AN/AN/A$10.83 per shareN/ARNAZTransCode TherapeuticsN/AN/AN/AN/A$86.32 per shareN/ASLSSELLAS Life Sciences Group$1M192.57N/AN/A($0.25) per share-7.72VTLVital TherapiesN/AN/AN/AN/A$0.29 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYBNCybin-$57.88M-$4.38N/AN/AN/AN/A-37.58%-36.59%N/ARNAZTransCode Therapeutics-$18.55MN/A0.00N/AN/AN/A-649.03%-281.34%N/ASLSSELLAS Life Sciences Group-$37.34M-$0.38N/AN/AN/AN/A-629.46%-178.65%8/12/2025 (Estimated)VTLVital Therapies-$41.47MN/A0.00∞N/AN/A-235.33%-182.35%N/ALatest VTL, SLS, CYBN, and RNAZ EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/21/2025Q4 2024RNAZTransCode Therapeutics-$2.00-$0.60+$1.40-$2.51$0.30 millionN/A5/13/2025Q1 2025SLSSELLAS Life Sciences Group-$0.1067-$0.07+$0.0367-$0.07N/AN/A3/20/2025Q4 2024SLSSELLAS Life Sciences Group-$0.1067-$0.08+$0.0267-$0.08N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCYBNCybinN/AN/AN/AN/AN/ARNAZTransCode TherapeuticsN/AN/AN/AN/AN/ASLSSELLAS Life Sciences GroupN/AN/AN/AN/AN/AVTLVital TherapiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYBNCybinN/A24.2424.24RNAZTransCode TherapeuticsN/A1.581.58SLSSELLAS Life Sciences GroupN/A2.262.26VTLVital TherapiesN/A6.976.97Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYBNCybin17.94%RNAZTransCode TherapeuticsN/ASLSSELLAS Life Sciences Group17.38%VTLVital Therapies15.52%Insider OwnershipCompanyInsider OwnershipCYBNCybin15.00%RNAZTransCode Therapeutics0.10%SLSSELLAS Life Sciences Group1.40%VTLVital Therapies33.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYBNCybin5021.48 million17.96 millionNot OptionableRNAZTransCode Therapeutics9833,000677,000Not OptionableSLSSELLAS Life Sciences Group1099.78 million69.54 millionNot OptionableVTLVital Therapies1042.37 millionN/ANot OptionableVTL, SLS, CYBN, and RNAZ HeadlinesRecent News About These Companies18,000 vulnerable children could lose ‘vital’ therapy as adoption fund faces axeMarch 31, 2025 | msn.comVeterans Deserve Access To Life-Changing Psychedelics Therapy: A Vital Solution For PTSD And HealingNovember 11, 2024 | benzinga.comRespiratory Therapy program continues to thrive at Vermont State UniversityNovember 6, 2024 | vermontbiz.comRespiratory Therapy program continues to thrive at Vermont State UniversityNovember 6, 2024 | vermontbiz.comLighthouse Center for Vital Living celebrates new buildingOctober 30, 2024 | duluthnewstribune.comAlternative Wellness Therapies in the Tahoe BasinOctober 11, 2024 | tahoedailytribune.comAddressing Trauma: A Vital Component in Behavioral HealthOctober 3, 2024 | ajmc.comVital Care Receives Strategic Investment From Berkshire Partners, Leonard Green & Partners, and Linden Capital PartnersAugust 1, 2024 | tmcnet.comVeterans lobbied for psychedelic therapy, but it may not be enough to save MDMA drug applicationJuly 26, 2024 | msn.comEnding TherapyMay 24, 2024 | psychologytoday.comMedication and TherapyMay 23, 2024 | psychologytoday.comVardhman Textiles Ltd.May 22, 2024 | wsj.comFDA’s Marks: Global Regulatory Convergence Vital to Cell & Gene Therapy OversightMay 11, 2024 | biospace.comVital Spa celebrates a year on Bridge StreetApril 28, 2024 | yahoo.comGuest opinion: Psychedelics as a vital path to healing for veteransApril 28, 2024 | heraldextra.comDon’t Forget About Vital Signs in Psychiatry VisitsMarch 12, 2024 | psychologytoday.comWhat is therapeutic recreation? Champaign counselors train to include it in their sessionsMarch 8, 2024 | yahoo.comTeen Therapy and Psychiatry Online: Hit or Miss?March 3, 2024 | medpagetoday.comVital Ltd VTLMarch 2, 2024 | morningstar.comThe Benefits of Teen Outpatient Programs for Behavioral HealthMarch 2, 2024 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVTL, SLS, CYBN, and RNAZ Company DescriptionsCybin NYSE:CYBN$8.34 +0.87 (+11.65%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$8.30 -0.04 (-0.42%) As of 08:12 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has research and collaboration agreement with TMS Neurohealth Centers Inc. for development of psychedelic compound-based therapeutics; Kernel for use of Kernel flow technology to measure neural activity; and Greenbook TMS to establish mental health centers. The company is headquartered in Toronto, Canada.TransCode Therapeutics NASDAQ:RNAZ$6.87 -0.10 (-1.43%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$7.17 +0.30 (+4.37%) As of 08:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.SELLAS Life Sciences Group NASDAQ:SLS$1.93 +0.04 (+2.12%) Closing price 05/27/2025 04:00 PM EasternExtended Trading$2.00 +0.07 (+3.37%) As of 08:16 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. SELLAS Life Sciences Group, Inc. is headquartered in New York, New York.Vital Therapies NASDAQ:VTLImmunic, Inc. develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. It focuses on ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. Its products include IMU-838, IMU-935, and IMU-856. The company is headquartered in San Diego, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Advance Auto Parts: Did Earnings Defuse Tariff Concerns? Apple Sinks After New 25% Tariff Announcement—What's The Bottom? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
